Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlations of EZH2 and SMYD3 gene polymorphisms with breast cancer susceptibility and prognosis.

Bioscience reports - 28 Feb 2018

Ma Shao-Jun, Liu Yan-Mei, Zhang Yue-Lang, Chen Ming-Wei, Cao Wei

Abstract excerpt

The aim of the present study was to investigate the correlation of enhancer of Zeste homolog 2 (EZH2) and SET and MYND domain containing 3 (SMYD3) gene polymorphisms with breast cancer susceptibility and prognosis. A total of 712 patients with breast cancer and 783 healthy individuals were selected. Normal breast epithelial cells MCF-10A and breast cancer cells MCF-7, MDA-MB-231, T47D, and Bcap-37 were cultured....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enhancer of Zeste Homolog 2 Protein
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone-Lysine N-Methyltransferase

Share to Lymphatic Metastasis

Share to MCF-7 Cells

Share to Minisatellite Repeats

Share to Neoplasm Staging

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 29089464
DOI: 10.1042/BSR20170656
PMCID: PMC5794497

Genes

SMYD3
SET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlations of EZH2 and SMYD3 gene polymorphisms with breast cancer susceptibility and prognosis.PMID 29089464Read ↗

Meta-analysis of Genetic polymorphism of Enhancer of Zeste Homolog2 gene in cancer susceptibility.Semantic proximity Read ↗

Analysis of EZH2 Genetic Variants on Triple-Negative Breast Cancer Susceptibility and Pathology.Semantic proximity Read ↗

SET and MYND Domain-Containing Protein 3 (SMYD3) Polymorphism as a Risk Factor for Susceptibility and Poor Prognosis in Ovarian Cancer.Semantic proximity Read ↗

The possible role of EZH2 and DNMT1 polymorphisms in sporadic triple-negative breast carcinoma in southern Chinese females.Semantic proximity Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

Functional relationship of SNP (Ala490Thr) of an epigenetic gene EZH2 results in the progression and poor survival of ER+/tamoxifen treated breast cancer patients.Semantic proximity Read ↗

Bioinformatics analysis of predictive value of EZH2 in early breast cancerSemantic proximity Read ↗

EZH2 genetic variants affect risk of gastric cancer in the Chinese Han population.Semantic proximity Read ↗

Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancerSemantic proximity Read ↗

TOX high mobility group box family member 3 rs3803662 and breast cancer risk: A meta-analysis.Semantic proximity Read ↗

EZH2 mutation is associated with the development of visceral metastasis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells.Semantic proximity Read ↗

Analysis on EZH2: mechanism identification of related CeRNA and its immunoassay in hepatocellular carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.